Work

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-125113

Authors: Brian J Ball, Christopher Famulare, Eytan M. Stein, Martin S. Tallman, Saar I. Gill, Benjamin M Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Najla Al Ali, David A Sallman, Eric Padron, Aaron D Goldberg, Rami S. Komrokji

Institutions: Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Hackensack University Medical Center, Moffitt Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2984459449

Cites:

Cited by: 4

Related to: 10